Eye injection showdown: which drug needs fewer shots for wet AMD?
NCT ID NCT04101877
First seen Nov 21, 2025 · Last updated May 12, 2026 · Updated 21 times
Summary
This study compares two drugs, bevacizumab and aflibercept, given as eye injections to treat wet age-related macular degeneration (AMD). About 402 adults aged 50 and older with wet AMD will receive one of the two drugs for two years. The goal is to see which drug requires fewer injections while still controlling the disease and preserving vision.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Vastra Gotaland Region, Sahlgrenska University Hospital, Department of Ophthalmology
Mölndal, Sweden
Conditions
Explore the condition pages connected to this study.